COGZF COGSTATE
- 0.792
- +0.002+0.23%
COGSTATE News
Cogstate (ASX:CGS) Is Experiencing Growth In Returns On Capital
Cogstate Ltd Announces Share Buy-Back Update
Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial
Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD
Cogstate Ltd Continues Share Buy-Back Initiative
Cogstate Ltd Continues Share Buy-Back Program
Cogstate (ASX:CGS) Shareholders Have Earned a 42% CAGR Over the Last Five Years
Cogstate Continues Aggressive Share Buy-Back
Cogstate Ltd Continues Share Buy-Back Effort
Cogstate Ltd Options Cease Amid Unmet Conditions
Cogstate Ltd Seeks Quotation for New Securities
Cogstate Continues Share Buy-Back Initiative
Cogstate Amends License Agreement With Eisai for Alzheimer's Treatment
Cogstate (ASX:CGS) has amended its global license agreement with Eisai Co. Ltd. to re-acquire rights to a technology that would allow it to build an integrated system for Alzheimer's treatment, accord
Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?
Cogstate Limited (ASX:CGS) Insiders Have Significant Skin in the Game With 50% Ownership
Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%
Shares of Cogstate (ASX:CGS) declined nearly 8% in recent trade despite the company reporting Thursday that the net attributable profit after tax in the six-month period ended Dec. 31, 2023, grew to $
Bullish Cogstate Insiders Loaded Up On US$4.47m Of Stock
Cogstate Ends Share Buyback Program
Cogstate (ASX:CGS) ended its share buyback program first disclosed last Feb. 23 as it enters a prohibited period as outlined in its share trading policy. Since the program began, the neurological asse
Canaccord Genuity Remains a Buy on Cogstate Ltd (COGZF)
Shareholders Will Probably Hold Off On Increasing Cogstate Limited's (ASX:CGS) CEO Compensation For The Time Being
Parkinson's Disease Psychosis Market Is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio
The dynamics of the Parkinson's disease psychosis market are anticipated to change in the coming years owing to the improvement in diagnosis methodologies, rising awareness of the disease, incrementa
Analysis
Price Target
No Data
